


Washington State Life Science Investment Report October 2025

A monthly report summarizing life science transactions in Washington State.


BY THE NUMBERS: **23** TRANSACTIONS
(YTD) TOTALING OVER **\$1.3B**



Deals Per Sector



Disclosed Funding By Sector



OCTOBER TOP TRANSACTIONS

Brooks.ai, a Seattle-area health technology startup that uses AI to help clinical teams to deliver remote care, raised a \$28M Series B round led by UMass Memorial Health and Morningside. Founded in 2015, Brooks' platform combines data analytics, automated nudges, and support from clinicians and health coaches to help patients manage chronic conditions from home ([GeekWire](#)).

NewDays, a Seattle startup using a generative AI therapy to treat people with mild dementia, has added \$4.5M to a recent seed funding round. Total funding is now \$11.5M after NewDays previously announced a \$7M investment in early September. The company offers telehealth visits with clinicians once or twice a month combined with frequent, personalized conversations with an AI companion called Sunny ([GeekWire](#)).

*Pending transactions noted here are included in financial data only upon closing.

OTHER TRENDS & HIGHLIGHTS

Seattle's 2025 Nobel Prize Winners, Mary Brunkow of the Institute for Systems Biology and Fred Ramsdell of Sonoma Biotherapeutics, have been awarded the 2025 Nobel Prize in Physiology or Medicine for their groundbreaking work on immune regulation. Their win marks two Nobel Prizes in two years for Washington's life sciences community, following David Baker's 2024 chemistry Nobel for protein design innovation ([GeekWire](#)).

Omeros secures up to \$2.1B licensing deal with Novo Nordisk in rare disease push. After pausing development of its MASP-3 inhibitor zaltenibart, Omeros now benefits as Novo Nordisk advances the therapy into a global phase 3 program for PNH and other rare disorders. The deal underscores the strength of Omeros' early work, with up to \$2.1B in value, including \$340M in near-term milestones ([FierceBiotech](#)).

SystImmune and Bristol Myers Squibb have hit a milestone, treating the first patient in a global trial of iza-bren for triple negative breast cancer. This triggered a \$250M payment from BMS, with up to \$7.6B possible ahead. Iza-bren, a first-in-class antibody-drug conjugate targeting EGFR and HER3, is being developed globally using strong data from China ([PR Newswire](#)).

TRANSACTIONS

Date	Company	Investors	Sector	Type	Amount	Location
8-Oct-25	NewDays Inc	ViewDifferent	Digital Health	Seed	\$4,500,000	Seattle
16-Oct-25	Brook Inc	Morningside Group, U Mass Memorial Health Care	Digital Health	Series B	\$28,000,000	Seattle
17-Oct-25	Xealth	Samsung Electronics	Digital Health	M&A	N/A	Seattle
Disclosed transactions monthly totals:						
October Total:					\$32,500,000	
September Total:					\$142,450,000	
August Total:					N/A	
July Total:					\$2,000,000	
June Total:					\$4,605,000	
May Total:					\$31,542,500	
April Total:					\$7,500,000	
March Total:					\$472,300,000	
February Total:					\$11,489,000	
January Total:					\$595,000,000	